99 The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluoruracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer

The CREAFORMO-004 study: A phase II study of HR070803 plus 5-fluoruracil/leucovorin and bevacizumab as second-line treatment in patients with metastatic colorectal cancer
Jianling Zou
https://storage.unitedwebnetwork.com/files/1083/c0bbb7b4f5acdbf3beadb46d5d8b6f3c.pptx
Submission Deadline: 1 February 2025